MPYS Protein Stimulants Pipeline

DelveInsight’s, “MPYS Protein Stimulants - Pipeline Insight, 2025,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in MPYS Protein Stimulants pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

MPYS Protein Stimulants Pipeline Outlook

MPYS Protein Stimulants Overview

Stimulator of interferon genes (STING), also known as transmembrane protein 173 (TMEM173) and MPYS/MITA/ERIS is a protein that in humans is encoded by the STING1 gene. STING plays an important role in innate immunity. STING induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites. Type I interferon, mediated by STING, protects infected cells and nearby cells from local infection by binding to the same cell that secretes it (autocrine signaling) and nearby cells (paracrine signaling.) It thus plays an important role, for instance, in controlling norovirus infection.

MPYS Protein Stimulants Pipeline Report Highlights

The MPYS Protein Stimulants Pipeline companies and academics are working to assess challenges and seek opportunities that could influence MPYS Protein Stimulants R&D. The therapies under development are focused on novel approaches for MPYS Protein Stimulants.

MPYS Protein Stimulants Drugs Chapters

This segment of the MPYS Protein Stimulants clinical trials report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Emerging MPYS Protein Stimulants Drugs

MK 1454: Merck & Co

STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. Currently, it is in Phase II stage of clinical trial evaluation to treat squamous cell cancer.

SYNB1891: Synlogic

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic strain of E. coli Nissle that produces cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. This mechanism can play a critical role in the initiation of an anti-tumor immune response via activation of APCs and presentation of tumor antigens. The bacterial chassis of SYNB1891 also stimulates the innate immune system by several other mechanisms, including via Toll-like receptors (TLRs), potentially adding to the magnitude of the overall immune response. While SYNB1891 has been engineered with safety features that are designed to prevent its replication unless supplemented with specific nutrients, the bacteria remain active for several days within the injected tumor to stimulate a local immune response. SYNB1891 is being evaluated in a Phase 1 clinical trial.

Further product details are provided in the report……..

MPYS Protein Stimulants Therapeutic Assessment

This segment of the MPYS Protein Stimulants pipeline report provides insights about the different MPYS Protein Stimulants drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on MPYS Protein Stimulants

There are approx. 20+ key companies which are developing the MPYS Protein Stimulants. The MPYS Protein Stimulants companies which have their MPYS Protein Stimulants drug candidates in the most advanced stage, i.e. Phase II include, Merck & Co.

MPYS Protein Stimulants Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

MPYS Protein Stimulants Route of Administration

MPYS Protein Stimulants pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. MPYS Protein Stimulants Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

MPYS Protein Stimulants Molecule Type

MPYS Protein Stimulants Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

MPYS Protein Stimulants Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Drugs	Company	Indication	RoA
Dazostinag	Takeda	Solid tumors	Intravenous
ACTM 838	Actym Therapeutics	Solid tumors	Intravenous
DN 015089	Shanghai De Novo Pharmatech	Solid tumors	Undisclosed
ONM 501	OncoNano Medicine/Regeneron	Lymphoma; Solid tumors	Intratumoral
BMS 986301	IFM therapeutics/Bristol Myers Squibb	Solid tumors	Intratumoural
IMGS 501	IMMUNOGENESIS	Solid tumours	Intravenous

Market Drivers for MPYS / STING Protein Stimulants Pipeline

Growing demand for novel immuno-oncology therapies

MPYS/STING pathway agonists are being developed to activate innate immunity and boost anti-tumour responses. For example, the STING agonist MK‑1454 is in clinical development for solid tumours.
Because existing checkpoint inhibitor therapies do not work for all patients, there is strong interest in new mechanisms like STING-agonism.

Expansion into infectious diseases and other immune indications

Beyond cancer, STING pathway modulation is seen as promising for infections (viral, bacterial) and potentially auto-immune disorders, broadening the addressable market. This creates more opportunity, which is driving investment in the pipeline.

Robust pipeline activity and multiple players entering the space

According to recent analysis, there are 10+ companies developing 11+ STING/MPYS protein stimulants.
A crowded and active pipeline indicates momentum, which tends to accelerate market growth.

Synergistic potential with existing therapies

STING agonists are being developed often in combination with check-point inhibitors or other immunotherapies (e.g., to “turn cold tumors hot”). This combinatorial potential increases clinical and commercial appeal of MPYS stimulants.
Since many oncology regimens are moving toward combination therapies, this is a favorable driver.

Technological advances improving delivery, safety and targeting

The STING pathway has historically had challenges (toxicity, systemic activation). Recent advances in nanoparticle delivery, intratumoural administration, prodrugs and targeted delivery are mitigating some risks — enabling broader development and hence market growth.

MPYS Protein Stimulants Clinical Trial Analysis

The MPYS Protein Stimulants clinical trials report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses MPYS Protein Stimulants manufacturers involved in developing key drugs.

MPYS Protein Stimulants Pipeline Development Activities

The MPYS Protein Stimulants pipeline drugs report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging MPYS Protein Stimulants drugs.

MPYS Protein Stimulants Pipeline Report Insights

• MPYS Protein Stimulants Pipeline Analysis
• MPYS Protein Stimulants Therapeutic Assessment
• MPYS Protein Stimulants Unmet Needs
• Impact of MPYS Protein Stimulants Drugs

MPYS Protein Stimulants Pipeline Report Assessment

• MPYS Protein Stimulants Pipeline Product Profiles
• MPYS Protein Stimulants Therapeutic Assessment
• MPYS Protein Stimulants Pipeline Assessment
• Inactive MPYS Protein Stimulants drugs assessment
• MPYS Protein Stimulants Unmet Needs

Key Questions in the MPYS Protein Stimulants Pipeline Report

• How many MPYS Protein Stimulants companies are developing MPYS Protein Stimulants drugs?
• How many MPYS Protein Stimulants drugs are developed by each company?
• How many emerging MPYS Protein Stimulants drugs are in mid-stage, and late-stage of development for the treatment of MPYS Protein Stimulants?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the MPYS Protein Stimulants therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing MPYS Protein Stimulants therapies?
• What are the clinical studies going on for MPYS Protein Stimulants and their status?
• What are the key designations that have been granted to the emerging MPYS Protein Stimulants drugs?